Dogwood Therapeutics, Inc. (DWTX)
Dogwood Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Alpharetta, GA, US. The stock last traded at $1.36, down 4.90% on the session, giving a market capitalisation of $45.7M. On trailing twelve-month figures it carries a trailing P/E of -0.15, a net margin of 0.0%. Its beta of 1.83 implies it has historically moved more than the broad market.
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.
Dogwood Therapeutics, Inc. is most often compared with the following Healthcare names: